NRx Pharmaceuticals eliminates all balance sheet debt by converting $5.4M to equity

NRX Pharmaceuticals, Inc.

Repaid remaining $5.4M debt to Anson Funds via equity conversion of common stock; no warrants or repricing mechanisms.
Original Anson loan was $16.2M; Company expects Dec 31 balance sheet to reflect zero convertible debt.
Debt-free capital structure positions NRx for accelerated growth with potential 2026 drug approvals and clinic expansions.
Press release dated Dec 2, 2025; Debt Cancellation Agreement executed Dec 29, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.